Biosimilar Reference Antibodies

At DIMA Biotech, we recognize the pivotal role of benchmark reference antibodies in developing superior biologic drugs. These antibodies streamline downstream efforts, aiding in the identification of crucial elements like cell lines and reagents. We offer a diverse range of biosimilar antibodies, meticulously assessed through binding assays. While intended for research purposes, they hold potential for various applications.
Explore DIMA’s biosimilar antibodies to advance your research and development. Join us in paving the way for biologic drug innovation.

Find the right BMK antibody for your assay

Featured BMK Targets

CD47	IL6	CD52	CD30	CD20	TNFRSF10B
CS1	TIM3	CD138	CD40	CD45	TweakR
CD123	PDL1	CD33	MSLN	TIGIT	CD22
CD38	B7-H3	CD27	CTLA4	BCMA	TIGIT
CD70	GPRC5D	EPHA3	Trop2	EGFR	AXL
PD-1	ICOS	CEACAM5	4-1BB	IL17RA	NKG2D
CA9	IL6R	CD40L	IL2RA	BAFF	BAFFR
CD37

Strict Quality Control

ELISA Binding Assay

Figure 1. ELISA plate pre-coated by Human PD1, mFc-His tagged protein (Cat# PME100025) can bind to Anti-PD-1 pembrolizumab biosimilar neutralizing antibody (Cat# BME100006) in a linear range of 0.24-6.49 ng/ml.

Flow Cytometry Analysis

Figure 2. HEK293 cell line transfected with human PD1(A) and irrelevant protein (B) were surface stained with anti-PD1 neutralizing antibody 1μg/ml (pembrolizumab, Cat# BME100006) followed by Alexa 488-conjugated anti-human IgG secondary antibody.